Aligos Therapeutics, Inc. (ALGS) income statement
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3055% below fair value
$1.30−0.06 (-4.41%)
Close on Nov 18, 2026Market cap $16.24MP/E –Yield –
Aligos Therapeutics, Inc. financial ratios
See a number that looks wrong?